These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21226316)

  • 1. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
    Nishikawa T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex.
    Fujihira T; Kanematsu S; Umino A; Yamamoto N; Nishikawa T
    Neurochem Int; 2007; 51(2-4):233-6. PubMed ID: 17662507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Endogenous D-serine in mammalian brains].
    Nishikawa T; Yamamoto N; Tsuchida H; Umino A; Kawaguchi N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2000 Feb; 20(1):33-9. PubMed ID: 10890022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycine modulators in schizophrenia.
    Javitt DC
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1067-72. PubMed ID: 12186269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of free D-serine in mammals and its biological relevance.
    Nishikawa T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(29):3169-83. PubMed ID: 21992750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
    Labrie V; Roder JC
    Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of strychnine-insensitive glycine receptor ligands in rats discriminating dizocilpine or phencyclidine from saline.
    Witkin JM; Steele TD; Sharpe LG
    J Pharmacol Exp Ther; 1997 Jan; 280(1):46-52. PubMed ID: 8996180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of group I metabotropic glutamate receptors in schizophrenia.
    Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
    Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of D-serine in the mammalian brain].
    Ying-Luan Z; Zhao YL; Mori H
    Brain Nerve; 2007 Jul; 59(7):725-30. PubMed ID: 17663143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of excitatory amino acids in neuropathology].
    Wikinski SI; Acosta GB
    Medicina (B Aires); 1995; 55(4):355-65. PubMed ID: 8728878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.